SCHEMBL10312993

SCHEMBL10312993

CCc1nc2c(s1)CN(C)CC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 4/20 0.48
RAD52 P43351 1/20 0.47
RECQL P46063 1/20 0.47
F10 P00742 1/20 0.39
KDM4E B2RXH2 4/20 0.38
ALDH1A1 P00352 3/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
HPGD P15428 2/20 0.37
LMNA P02545 1/20 0.37
CYP2C19 P33261 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
EPHA2 P29317 1/20 0.37
KDR P35968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12344032 0.85 RAD52 (0.38) GRM5RAD52RECQLNPC1RAB9A
SCHEMBL29086185 0.85 GRM5 (0.47) GRM5RAD52RECQLF10KDM4E
SCHEMBL30620417 0.85 GRM5 (0.47) GRM5RAD52RECQLF10KDM4E
SCHEMBL16286090 0.83 RAD52 (0.69) GRM5RAD52RECQLKDM4EALDH1A1
SCHEMBL24253349 0.82 GRM5 (0.45) GRM5RAD52RECQLF10KDM4E
SCHEMBL16286086 0.81 RAD52 (0.50) GRM5RAD52RECQLKDM4EALDH1A1
SCHEMBL17088085 0.78 RAD52 (0.50) GRM5RAD52RECQLKDM4EALDH1A1
SCHEMBL29086322 0.77 GRM5 (0.41) GRM5RAD52RECQLF10KDM4E
SCHEMBL16286098 0.77 NPC1 (0.51) GRM5RAD52RECQLALDH1A1KMT2A
SCHEMBL29011049 0.77 GRM5 (0.44) GRM5RAD52RECQLF10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3954681-A1 SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK Bristol-Myers Squibb Company (US) 2022-02-16 EP disclosed
WO-2020228649-A1 SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 上海海雁医药科技有限公司 2020-11-19 WO disclosed
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof HELSINN HEALTHCARE SA (CH) 2017-09-28 US disclosed
US-8377974-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-02-19 US disclosed
US-20120178733-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178733-A1 FACTOR XA INHIBITORS TFPI, F12, F11 GRM5 4015/4885RAD52 4249/4885RECQL 2145/4885
US-20170275301-A1 Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof UTS2R, GHSR, GRPR GRM5 964/4885RAD52 2684/4885RECQL 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.